Oncotarget

Reviews:

Homeodomaininteracting protein kinase 2 HIPK2: a promising target for anticancer therapies

PDF  |  Full Text  |  How to cite

Oncotarget. 2017; 8:20452-20461. https://doi.org/10.18632/oncotarget.14723

Metrics: PDF 2674 views  |  Full Text 4287 views

Yuanyuan Feng1,*, Lihong Zhou1,*, Xiaoting Sun1 and Qi Li1

1 Department of Medical Oncology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

* These authors have contributed in equal measure as the first author

Correspondence to:

Qi Li, email:

Keywords: HIPK2; cancer; p53; apoptosis; angiogenesis

Received: September 02, 2016 Accepted: January 04, 2017 Published: January 18, 2017

Abstract

The HIPK2 (serine/threonine homeodomain-interacting protein kinase 2) is a “caretaker” gene, its inactivation increases tumorigenicity while its activation inhibits tumor growth. This report reviews the anti-tumorigenic mechanisms of HIPK2, which include promotion of apoptosis, inhibition of angiogenesis in hypoxia, prevention of tumor invasion/metastasis and attenuation of multidrug resistance in cancer. Additionally, we summarize conditions or factors that may increase HIPK2 activity.